Skip to content
TheChatArchiveThe Chat Archive
o3-2025-04-16· OpenAIHugging Face LMArena Human Preference 140K

What are soms investigational proteins that could be targetted for treating anxiety…

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Qwenqwq-32b’s answer.
  1. User

    What are soms investigational proteins that could be targetted for treating anxiety disorders

  2. Assistant

    Below is a “scouting report” on a dozen proteins that researchers are probing as future anxiolytic targets. None of the compounds mentioned are yet approved for routine clinical use in anxiety disorders; most are in early‑phase trials or still pre‑clinical. Nevertheless, they illustrate the diversity of mechanisms scientists are pursuing beyond the classic benzodiazepine / SSRI playbook.

    #Protein / Receptor (Gene)Normal RoleWhy It Looks Promising for AnxietyExample Investigational Agent(s)Development Status*
    1Corticotropin‑Releasing Factor receptor‑1 (CRF₁; CRHR1)Master regulator of the HPA “stress axis”; drives cortisol releaseBlocking CRF₁ may blunt stress‑induced hyper‑arousal without sedatingPexacerfont, VerucerfontPhase II (mixed results)
    2Orexin / Hypocretin receptor‑1 (OX₁R; HCRTR1)Promotes wakefulness & vigilanceSelective OX₁ antagonists calm threat‑vigilance without the sleepiness seen with dual OX₁/OX₂ blockersACT‑539313, JNJ‑61393215Phase I–II
    3Fatty‑Acid Amide Hydrolase (FAAH)Degrades anandamide (endogenous cannabinoid)Inhibitors raise anandamide → CB₁‑mediated anxiolysis, but without THC‑like intoxicationPF‑04457845, JNJ‑42165279Phase I–II (cautious after BIA 10‑2474 incident)
    4Metabotropic glutamate receptor‑5 (mGluR5; GRM5)Modulates excitatory synaptic plasticityNegative allosteric modulators (NAMs) dampen over‑active glutamate circuits implicated in worry & ruminationBasimglurant (RG7090), dipraglurantPhase II for mood; anxiety data emerging
    5Metabotropic glutamate receptor‑2/3 (mGluR2/3; GRM2/3)Presynaptic “brake” on glutamate releaseOrthosteric agonists & positive modulators curb stress‑evoked glutamate surgesLY‑354740, XEN‑1101Phase II (panic / GAD)
    6Neuropeptide‑Y receptor‑Y1 (NPY Y₁; NPY1R)Part of body’s endogenous “resilience” peptide systemY₁ agonists produce robust anxiolysis in rodents even under extreme stress paradigmsIntranasal NPY analogs, PYY‑based peptidomimeticsPre‑clinical ↦ early human PoC
    7Transient Receptor Potential Vanilloid‑1 (TRPV1)Heat/capsaicin sensor; also modulates glutamate & GABA releaseTRPV1 antagonists plus partial agonists (desensitizers) reduce amygdala excitabilitySB‑705498, capsazepine analogsPre‑clinical
    8Kappa‑Opioid Receptor (KOR; OPRK1)Mediates dysphoria & stress‑induced drug seekingKOR antagonism can lift negative affect & has synergy with SSRIsAticaprant (LY2456302), BTRX‑335140Phase II (depression/anxiety)
    9Delta‑subunit–containing GABAₐ receptors (α4βδ, α6βδ)Extrasynaptic tonic inhibition, especially in thalamus & hippocampusSelective positive modulators give anxiolysis with little sedation / abuseGaboxadol analogs, SAGE‑689Pre‑clinical
    10Brain‑Derived Neurotrophic Factor receptor TrkB (NTRK2)Drives synaptic plasticity & fear extinctionSmall‑molecule TrkB agonists accelerate exposure‑based therapy effects7,8‑Dihydroxyflavone, R13Pre‑clinical ↦ Phase I
    11Glyoxalase‑1 (GLO1)Detoxifies methylglyoxal; intersects with GABA metabolismPartial inhibition raises methylglyoxal, an endogenous GABAₐ modulator → reduced anxiety in micepBBG, APH‑701Pre‑clinical
    12Histone Deacetylase‑3 (HDAC3)Epigenetic “brake” on gene expressionHDAC3 inhibition enhances fear‑extinction memory and may prevent relapseRGFP‑966, CI‑994Pre‑clinical

    *Status as of Q2‑2024; pipeline moves fast, so always verify recent updates.

    Key Themes & Take‑aways • Stress‑axis modulators: CRF₁ and KOR antagonists aim straight at the endocrine and dynorphin dysregulation seen in chronic anxiety.

    • Glutamate tuning: mGluR2/3 agonists and mGluR5 NAMs both recalibrate excitatory drive but from opposite directions (pre‑ vs post‑synaptic).

    • Endocannabinoid & neuropeptide “buffer” systems: FAAH blockers and NPY agonists leverage natural resilience pathways rather than brute‑force inhibition.

    • Circuit‑selective GABAergic strategies: Targeting δ‑subunit extrasynaptic receptors tries to replicate benzodiazepine relief minus cognitive slowing or dependence.

    • Plasticity enhancers: TrkB agonists, HDAC3 inhibitors, even low‑dose psychedelics (not shown) focus on accelerating extinction and reconsolidation rather than continuous symptom suppression.

    Caveats & Challenges • Translational gap: Many targets show stellar rodent data but falter in humans because of species differences in circuit engagement.

    • Side‑effect balancing act: E.g., OX₁ antagonists must avoid narcoleptic‐like drowsiness; CRF₁ blockers can cause adrenal effects.

    • Biomarker needs: For several pathways (NPY, HDAC3) there are no easy blood/CSF readouts, making dose‑finding tricky.

    • Patient stratification: Sub‑groups (e.g., high‑stress CRF‑driven vs glutamate‐driven worry) may respond differently; precision psychiatry is still emerging.

    Where to Go Next? If you’re thinking about research or drug‑development angles, you might…

    1. Track combo strategies: e.g., low‑dose FAAH inhibitor + exposure therapy, or TrkB agonist + CBT to lock in learning.
    2. Explore PET ligands as companion diagnostics (CRF₁, mGluR5, OX₁ tracers exist).
    3. Examine sex‑specific pathways (NPY and δ‑GABAₐ effects differ between males/females in pre‑clinical work).
    4. Keep an eye on novel delivery tech (intranasal peptides, targeted viral vectors for GLO1 knock‑down).

    Let me know if you’d like deeper dives into any of these targets, the chemistry of representative compounds, or current clinical‑trial read‑outs.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.